← Back to Search

Monoclonal Antibodies

Durvalumab + SoC chemotherapy for Non-Small Cell Lung Cancer (MERMAID-1 Trial)

Phase 3

Waitlist Available

Led By Solange Peters

Research Sponsored by AstraZeneca

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up approximately 6 years

Awards & highlights

MERMAID-1 Trial Summary

This trial is testing whether a new immunotherapy drug can help prevent cancer from coming back in patients who have had surgery for early-stage lung cancer.

MERMAID-1 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ approximately 6 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~approximately 6 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 6 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

DFS in FAS (using Investigator assessments according to RECIST 1.1)

Secondary outcome measures

DFS in MRD+ analysis set (using Investigator assessments according to RECIST 1.1)

OS in MRD+ analysis set and in FAS

MERMAID-1 Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Durvalumab + SoC chemotherapyExperimental Treatment1 Intervention

Intravenous administration of Experimental and Standard of Care Therapy

Group II: Placebo + SoC chemotherapyPlacebo Group1 Intervention

Intravenous administration of Placebo and Standard of Care Therapy

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Durvalumab + SoC chemotherapy

2020

Completed Phase 3

~90

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor

4,257 Previous Clinical Trials

288,593,697 Total Patients Enrolled

Solange PetersPrincipal InvestigatorCentre Hospitalier Universitaire Vaudois (CHUV)

1 Previous Clinical Trials

55 Total Patients Enrolled

Charles SwantonPrincipal InvestigatorFrancis Crick Institute

3 Previous Clinical Trials

894 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA cleared Durvalumab in combination with standard chemotherapy for use?

"Durvalumab + SoC chemotherapy was given a safety score of 3 by our analysts at Power. This is because Phase 3 trials have some data backing up the efficacy of the medication and there is data from multiple rounds supporting its safety."

Answered by AI

Are there other instances where Durvalumab has been combined with SoC chemotherapy?

"Durvalumab in combination with standard of care chemotherapy was first studied a decade ago, in 2010. To date, there have been 106 completed studies with 338 currently active ones. A large concentration of these active studies are being undertaken in Nashville, Tennessee."

Answered by AI

If I wanted to help test this new treatment, what would I need to do?

"Researchers are looking for 89 individuals aged 18-130 who have non-small-cell lung carcinoma that meets the following stage requirements: resectable (stage II-III). Furthermore, all potential participants must be able to provide informed consent, including compliance with ICFs and the study protocol. Finally, patients must have had a complete resection of the primary NSCLC."

Answered by AI

Could you tell me if people who are younger than 50 years old can participate in this experiment?

"Patients must be aged 18-130 to enroll in this clinical trial. There are 26 trials for patients under 18 and 1725 trials for patients aged 65 and over."

Answered by AI

When is the combination of Durvalumab and SoC chemotherapy used?

"Durvalumab + SoC chemotherapy is mostly used to treat stage iii non-small cell lung cancer that cannot be removed surgically. It can also be used to treat metastatic ureter urothelial carcinoma and advance directives."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

2020. "Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04385368.